NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
AIN Albany International Corp
BTVRF BlueRush Inc
GOLF Acushnet Holdings Corp
AA Alcoa Corp
CNCE Concert Pharmaceuticals Inc
BL Blackline Inc
DFEN Direxion Daily Aerospace & Defense Bull 3X Shares Direxion Daily Aerospace
NVRO Nevro Corp
DBI Designer Brands Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
$4.54
Day's Change
-0.09 (-1.94%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.85
Day's Low
4.35
Volume
(Light)
Volume:
238,017

10-day average volume:
6,405,823
238,017

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

5:19 pm ET December 1, 2021 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Regeneron Pharmaceuticals Inc. (REGN) shed 0.93% to $630.59 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.18% to 4,513.04 and Dow Jones Industrial Average falling 1.34% to 34,022.04. This was the stock's second consecutive day of losses. Regeneron Pharmaceuticals Inc. closed $56.03 below its 52-week high ($686.62), which the company achieved on September 3rd.

The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 1.38% to $158.08, Novartis AG ADR (NOVN.EB) rose 0.15% to $79.82, and Amgen Inc. (AMGN) rose 0.97% to $200.80. Trading volume (731,637) remained 47,671 below its 50-day average volume of 779,308.

Data source: Dow Jones Market Data, FactSet. Data compiled December 1, 2021.

-MarketWatch Automation

	

(END) Dow Jones Newswires

December 01, 2021 17:19 ET (22:19 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.